Triple-negative breast cancer is one of the most difficult forms of breast cancer to treat. This project will investigate whether a protein called CDK2 helps cancer cells resist treatment and continue growing. The findings could help researchers identify patients who may benefit from new targeted therapies and improve future treatment approaches.

By learning more about how aggressive breast cancers survive and resist treatment, this research could help pave the way for more effective therapies and better outcomes for patients.